Citrus bergamia

Citrus bergamia (Calabrian bergamot) is rich in unique flavonoids — neoeriocitrin, naringin, neohesperidin, melitidin, and brutieridin — collectively known as the Bergamot Polyphenolic Fraction (BPF). The body of evidence includes Mollace et al. 2011 (single RCT, 237 patients), Toth et al. 2016 (6-month prospective study), and the Lamiquiz-Moneo et al. 2020 systematic review (PMID 31670973, qualitative synthesis of 12 trials). Published LDL reductions span ~8-40% at 500-1500 mg/day BPF over 30-180 days, with most pronounced effects in metabolic syndrome and mild hypercholesterolemia. Independent replications cluster at the lower end of that range; the highest published effect sizes come from the Mollace group + BIONAP (Bergavit producer). Mechanism: HMG-CoA reductase inhibition (statin-like), AMPK activation, and preclinical evidence for PCSK9 downregulation. Safety: bergamot contains furanocoumarins (bergamottin, 6,7-dihydroxybergamottin) that irreversibly inhibit intestinal CYP3A4 for >24 hours — the same mechanism as the grapefruit interaction. Clinically meaningful drug interactions: statins (simvastatin, atorvastatin), calcium-channel blockers, tacrolimus, cyclosporine, and other CYP3A4 substrates. Some BPF preparations are furanocoumarin-reduced but not all — check the label. Mild GI complaints at higher doses. 'Green bergamot' refers to unripe-fruit extract marketed for higher polyphenol density.

Moderate clinical evidence. Lipid effects directionally consistent across trials but effect-size range is wide (~8-40% LDL reduction); largest effects concentrated in the Mollace group with industry funding, independent replications cluster lower. Furanocoumarin content creates a real CYP3A4 drug-interaction risk with statins and others